BOLT · NASDAQ
Bolt Biotherapeutics (BOLT) Stock Price & Fundamentals
Bolt Biotherapeutics (BOLT) closed at $419.58 on Oct 9, 2026, down 0.71% from the previous close of $422.57.
Share price, past year
1Y +27.81%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $419.58 |
| Sep 30, 2026 | $427.91 |
| Aug 31, 2026 | $427.42 |
| Jul 31, 2026 | $430.49 |
| Jun 30, 2026 | $397.96 |
| May 29, 2026 | $391.53 |
| Apr 30, 2026 | $366.25 |
| Mar 31, 2026 | $372.54 |
| Feb 27, 2026 | $359.41 |
| Jan 30, 2026 | $342.09 |
| Dec 31, 2025 | $346.99 |
| Nov 28, 2025 | $348.47 |
| Oct 31, 2025 | $338.40 |
Key statistics
- Market cap
- $808.26M
- P/E (TTM)
- —
- EPS (TTM)
- —
- Revenue (TTM)
- $4.70M
- Net income (TTM)
- −$28.74M
- Shares outstanding
- 1.9M
- Dividend yield
- —
- 52-week range
- $327.06 – $444.70
Bolt Biotherapeutics's market cap is $808.26M, based on a share price of $419.58 and 1.9M shares outstanding as of Jun 30, 2026.
Financials
Bolt Biotherapeutics reported revenue of $7.70M for fiscal 2025, up 0.07% from fiscal 2024.
Bolt Biotherapeutics reported a net loss of $33.38M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $7.70M | +0.1% | −$33.38M | −433.7% | −$17.85 | −$39.92M |
| FY2024ended Dec 31, 2024 | $7.69M | −2.4% | −$63.12M | −820.8% | −$33.06 | −$61.33M |
| FY2023ended Dec 31, 2023 | $7.88M | +37.5% | −$69.20M | −878.6% | −$0.0915 | −$69.73M |
| FY2022ended Dec 31, 2022 | $5.73M | +354.7% | −$88.10M | −1,537.8% | −$0.118 | −$78.46M |
| FY2021ended Dec 31, 2021 | $1.26M | +445.5% | −$98.59M | −7,824.7% | −$0.1485 | −$59.40M |
| FY2020ended Dec 31, 2020 | $231.00K | — | −$60.73M | −26,289.2% | — | −$50.57M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $5.00K | −$7.72M | −$4.57 |
| Q1 FY2026ended Mar 31, 2026 | $26.00K | −$7.24M | −$4.31 |
| Q4 FY2025ended Dec 31, 2025 | $2.50M | −$6.63M | — |
| Q3 FY2025ended Sep 30, 2025 | $2.17M | −$7.14M | −$3.72 |
| Q2 FY2025ended Jun 30, 2025 | $1.80M | −$8.56M | −$4.46 |
| Q1 FY2025ended Mar 31, 2025 | $1.22M | −$11.04M | −$5.76 |
| Q4 FY2024ended Dec 31, 2024 | $0.00 | −$15.94M | — |
| Q3 FY2024ended Sep 30, 2024 | $1.14M | −$15.18M | −$7.93 |
Company profile
- Name
- Bolt Biotherapeutics, Inc.
- Ticker
- BOLT
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 900 Chesapeake Drive, Redwood City, CA 94063
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001641281
Recent SEC filings
- Oct 6, 2026
- Aug 11, 2026
- Aug 11, 2026
- Jun 11, 2026
- May 12, 2026
- May 12, 2026
- Mar 12, 2026
- Mar 12, 2026
Frequently asked questions
What is Bolt Biotherapeutics's stock price?
Bolt Biotherapeutics (BOLT) closed at $419.58 on Oct 9, 2026, down 0.71% from the previous close of $422.57.
What is Bolt Biotherapeutics's market cap?
Bolt Biotherapeutics's market cap is $808.26M, based on a share price of $419.58 and 1.9M shares outstanding as of Jun 30, 2026.
How much revenue does Bolt Biotherapeutics make?
Bolt Biotherapeutics reported revenue of $7.70M for fiscal 2025, up 0.07% from fiscal 2024.
Does Bolt Biotherapeutics pay a dividend?
Bolt Biotherapeutics's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Bolt Biotherapeutics, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures